Lilly and Foghorn collaborate on novel oncology targets

By The Science Advisory Board staff writers

December 14, 2021 -- Loxo Oncology at Lilly and Foghorn Therapeutics will collaborate to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control platform. The collaboration includes Foghorn's BRM oncology program, an additional undisclosed oncology target, as well as three additional discovery programs.

Under the terms of the agreement, Foghorn will receive upfront consideration of $300 million in cash and an equity investment by Lilly of $80 million in Foghorn common shares at a price of $20 per share. The terms of the transaction have cleared the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Foghorn's BRM-selective program is being developed to address BRG1-mutated cancers using two distinct approaches, including protein degradation and enzymatic inhibition. Foghorn's proprietary Gene Traffic Control platform is a tool for understanding and modulating the chromatin regulatory system.

Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories' oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.